Current and future therapies for myasthenia gravis

Drugs and Aging

Volumn 11, Issue 2, 1997, Pages 132-139

  Yi, Qing ^a   Lefvert, Ann Kari ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT;

AUTOIMMUNITY; HUMAN; IMMUNOTHERAPY; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; PRIORITY JOURNAL; REVIEW;

EID: 0030859338     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199711020-00005     Document Type: Review

References (61)

1. Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330: 1797-810
2. Almon RR, Andrew CG, Appel SH. Serum globulin in myasthenia gravis: inhibition of α-bungarotoxin binding to acetylcholine receptors. Science 1974; 186: 55-7
3. Lefvert AK, Bergström K, Matell G, et al. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry 1978; 41: 394-403
4. Hoblfeld R, Kalies I, Kohleisen B, et al. Myasthenia gravis: stimulation of antireceptor autoantibodies by autoreactive T cell lines. Neurology 1986; 36: 618-21
5. Grob D, Brunner NG, Namba T. The natural course of myasthenia gravis and effect of therapeutic measures. Ann N Y Acad Sci 1981; 377: 652-69
6. Walker M. Treatment of myasthenia gravis by physostigmine. Lancet 1934; 1: 1200-1
7. Castleman B. The pathology of the thymus gland in myasthenia gravis. Ann N Y Acad Sci 1966: 135: 496-503
8. Papatestas AE, Genkins G, Kornfeld P, et al. Effects of thymectomy in myasthenia gravis. Ann Surg 1987; 206: 79-88
9. Beghi E, Antozzi C, Batocchi AP, et al. Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. J Neurol Sci 1991; 106: 213-20
10. Wekerle H, Ketelsen U-P. Intrathymic pathogenesis and dual genetic control of myasthenia gravis. Lancet 1977; 1: 678-80
11. Sommer N, Willcox N, Hartcourt GC, et al. Myasthenic thymus and thymoma are selectively enriched in acctylcholine receptor-reactive T cells. Ann Neurol 1990; 28: 312-9
12. Ahlberg R, Yi Q, Pirskanen R, et al. Effect of thymectomy on T and B lymphocytes in myasthenia gravis. J Neuroimnunol 1997; 74: 45-54
13. Simon HE. Myasthenia gravis: effect of treatment with anterior pituitary extract. JAMA 1935; 104: 2065-6
14. Arsure E, Brunner MG, Namba T, et al. High dose intravenous methylprednisolone in myasthenia gravis. Arch Neurol 1985; 42: 1149-53
15. Fonseca V, Harvard CW. Long term treatment of myasthenia gravis with azathioprine. Postgrad Med J 1990; 66: 102-5
16. Matell G. Immunosuppressive drugs: azathioprine in treatment of myasthenia gravis. Ann N Y Acad Sci 1987; 505: 588-94
17. Tindall RA, Phillips T, Rollins JA, et al. A clinical trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci 1993; 681: 539-51
18. Perez MC, Buol WL, Mercado-Danguilan C, et al. Stable remission in myasthenia gravis. Neurology 1981; 31: 32-7
19. Gajdos P, Outin H, Elkharrat D, et al. High-dose intravenous gamma globulin for myasthenia gravis. Lancet 1984; 1: 406-7
20. Bergström K, Frankson C, Matell G, et al. The effect of thoracic duct lymph drainage in myasthenia gravis. Eur Neurol 1973; 9: 157-67
21. Dau PC. Response to plasmapheresis and immunosuppressive drug therapy in 60 myasthenia gravis patients. Ann N Y Acad Sci 1981; 377: 700-8
22. Shibuya N, Sato T, Osame M, et al. Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry 1994; 57: 578-81
23. Bach J-F. Immunosuppressive therapy of autoimmune diseases. Immunol Today 1993; 14: 322-6
24. Lorenzon P, Ruzzier F, Caratsch CG, et al. Interleukin-2 lengthens extrajunctional acetylcholine receptor channel open time in mammalian muscle cells. Pflugers Arch 1991; 419: 380-5
25. Gu D, Wogensen L, Calcutt NA, et al. Myasthenia gravis-like syndrome induced by expression of interferon-γ in the neuromuscular junction. J Exp Med 1995; 181: 547-57
26. Swain SL, Dialynas DP, Fitch FW, et al. Monoclonal antibody to L3T4 blocks the function of T cells specific for class 2 major histocompatibility complex antigens. J Immunol 1984; 132: 1118-23
27. Christadoss P, Dauphinee MJ. Immunotherapy for myasthenia gravis: a murine model. J Immunol 1986; 136: 2437-40
28. Waldmann H, Manipulation of T-cell responses with monoclonal antibodies. Annu Rev Immunol 1989; 7: 407-44
29. Ahlberg R, Yi Q, Pirskanen R, et al. Treatment of myasthenia gravis with anti-CD4 antibody: improvement correlates to decreased T-cell autoreactivity. Neurology 1994; 44: 1732-7
30. Steinberg AD, Raveche ES, Laskin CA, et al. Systemic lupus erythematosas: insights from animal models. Ann Intern Med 1984; 100: 714-27
31. Peters M, Walling DM, Kelly K, et al, Immunological effects of interferon-α in man: treatment with recombinant interferon-α suppresses in vitro immunoglobulin production in patients with chronic type B hepatitis. J Immunol 1986; 137: 3147-52
32. O'Gorman MR, Oger J, Kastrukoff LF. Reduction of immunoglobulin G secretion in vitro following long term lymphoblastoid interferon (Wellferon) treatment in multiple sclerosis patients. Clin Exp Immunol 1987; 67: 66-75
33. Shenoy M, Baron S, Wu B, et al. IFN-α treatment suppresses the development of experimental autoimmune myasthenia gravis. J Immunol 1995; 154: 6203-8
34. Batocchi AP, Evoli A, Servidei S, et al. Myasthenia gravis during interferon alpha therapy. Neurology 1995; 45: 382-3
35. Piccolo G, Franciotta D, Versino M, et al. Myasthenia gravis in a patient with chronic active hepatitis C during interferon-α treatment [letter]. J Neurol Neurosurg Psychiatry 1996; 60: 348
36. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174: 561-9
37. Freeman GJ, Borriello F, Hodes RJ, et al. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 1993; 262: 907-9
38. Tan P, Anasetti C, Hansen JA, et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993; 177: 165-73
39. McArthur JG, Raulet DH, CD28-induced costimulation of T helper type 2 cells mediated by induction of responsiveness to interleukin 4. J Exp Med 1993; 178: 1645-53
40. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992; 89: 1102-5
41. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA41g. Science 1994; 265: 1225-7
42. Nishikawa K, Linsley PS, Collins AB, et al. Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur J Immunol 1994; 24: 1249-54
43. McIntosh KR, Linsley PS, Drachman D. Immunosuppression and induction of anergy by CTLA41g in vitro: effects on cellular and antibody responses of lymphocytes from rats with experimental autoimmune myasthenia gravis. Cell Immunol 1995; 166: 108-12
44. Brocke S, Brautbar C, Steinman L, et al. In vitro proliferative responses and antibody titers specific to human acetylcholine receptor synthetic peptides in patients with myasthenia gravis and relation to HLA class II genes. J Clin Invest 1988; 82: 1894-900
45. Melms A, Chrestel S, Schalke BCG, et al. Autoimmune T lymphocytes in myasthenia gravis: determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J Clin Invest 1989; 83: 785-90
46. Protti MP, Manfredi AA, Straub C, et al. Immunodominant regions for T help-cell sensitization on the human nicotinic re- ceptor α subunit in myasthenia gravis. Proc Natl Acad Sci U S A 1990; 87: 7792-6
47. Åhlberg R, Yi Q, Eng H, et al. T-cell epitopes on the human acetylcholine receptor α-subunit residues 10-84 in myasthenia gravis. Scand J Immunol 1992; 36: 435-42
48. Reim J, McIntosh K, Martin S, et al. Specific immunotherapeutic strategy for myasthenia gravis: targeted antigen-presenting cells. J Neuroimmunol 1992; 41: 61-70
49. Katz-Levy Y, Kirshner SL, Sela M, et al. Inhibition of T-cell reactivity to myasthenogenic epitopes of the human acetylcholine receptor by synthetic analogs. Proc Natl Acad Sci U S A 1993; 90: 7000-4
50. Zisman E, Katz-Levy Y, Dayan M, et al. Peptide analogs to pathogenic epitopes of the human acetylcholine receptor α-subunit as potential modulators of myasthenia gravis. Proc Natl Acad Sci U S A 1996; 93: 4492-7
51. Mowat AM. The regulation of immune responses to dietary protein antigens. Immunol Today 1987; 8: 93-8
52. Thompson HS, Staines NA, Could specific oral tolerance be a therapy for autoimmune disease? Immunol Today 1990; 11: 396-9
53. Wang ZY, Qiao J, Link H. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol 1993; 44: 209-14
54. Okumura S, McIntosh K, Drachman DB. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis. Ann Neurol 1994; 36: 704-13
55. Ma C-G, Zhang G-X, Xiao B-G, et al. Suppression of experimental autoimmune myasthenia gravis by nasal adminis- tration of acetylcholine receptor. J Neuroimmunol 1995; 58: 51-60
56. Weiner HC, MacKin GA, Matsui M, et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259: 1321-4
57. Trentham DE, Dynesium-Trentham A, Orav EJ, et al. Effects of oral administration of type H collagen on rheumatoid arthritis. Science 1993; 261: 1727-30
58. Souvoryon MD, Fuchs S. Antiidiotypic antibodies in the regulation of experimental myasthenia gravis. Ann N Y Acad Sci 1987; 505: 676-82
59. Agius MA, Richman DP. Suppression of development of experimental autoimmune myasthenia gravis with isogeneic monoclonal antiidiotypic antibody. J Immunol 1986; 137: 2195-8
60. Lennon V, Lambert E. Monoclonal antibody to Achr: evidence for a dominant idiotype and the requirement of complement for pathogenesis. Ann N Y Acad Sci 1981; 377: 77-96
61. Killen JA, Hochswender SM, Lindstrom J. The main immunogenic region of Achr does not provoke the formation of antibodies of a predominant idiotype. J Neuroimmunol 1985; 9: 229-41